# Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®

> **NCT06310824** · PHASE1 · COMPLETED · sponsor: **Xentria, Inc.** · enrollment: 225 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** MAB-22
- **DRUG:** EU-Prolia®
- **DRUG:** US-Prolia®

## Key facts

- **NCT ID:** NCT06310824
- **Lead sponsor:** Xentria, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-05
- **Primary completion:** 2025-07-22
- **Final completion:** 2025-07-22
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06310824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06310824, "Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06310824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*